期刊
MOLECULAR GENETICS & GENOMIC MEDICINE
卷 7, 期 10, 页码 -出版社
WILEY
DOI: 10.1002/mgg3.961
关键词
DNM1L; epileptic encephalopathy; HSAN; intradermal histamine test; self-injury; whole genome sequencing
资金
- BCCH Foundation as 1st Collaborative Area of Innovation
- Genome BC [SOF-195]
- CIHR [301221]
- Alberta Children's Hospital Research Institute Foundation
- Canadian Institute of Health Research (CIHR) [MOP-102600]
Background Profiling the entire genome at base pair resolution in a single test offers novel insights into disease by means of dissection of genetic contributors to phenotypic features. Methods We performed genome sequencing for a patient who presented with atypical hereditary sensory and autonomic neuropathy, severe epileptic encephalopathy, global developmental delay, and growth hormone deficiency. Results Assessment of the variants detected by mapped sequencing reads followed by Sanger confirmation revealed that the proband is a compound heterozygote for rare variants within RETREG1 (FAM134B), a gene associated with a recessive form of hereditary sensory and autonomic neuropathy, but not with epileptic encephalopathy or global developmental delay. Further analysis of the data also revealed a heterozygous missense variant in DNM1L, a gene previously implicated in an autosomal dominant encephalopathy, epilepsy, and global developmental delay and confirmed by Sanger sequencing to be a de novo variant not present in parental genomes. Conclusions Our findings emphasize the importance of genome-wide sequencing in patients with a well-characterized genetic disease with atypical presentation. This approach reduces the potential for misdiagnoses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据